MX2016006657A - Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis. - Google Patents
Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.Info
- Publication number
- MX2016006657A MX2016006657A MX2016006657A MX2016006657A MX2016006657A MX 2016006657 A MX2016006657 A MX 2016006657A MX 2016006657 A MX2016006657 A MX 2016006657A MX 2016006657 A MX2016006657 A MX 2016006657A MX 2016006657 A MX2016006657 A MX 2016006657A
- Authority
- MX
- Mexico
- Prior art keywords
- gastrin
- prevention
- treatment
- netazepide
- osteoporosis
- Prior art date
Links
- 102100021022 Gastrin Human genes 0.000 title abstract 6
- 108010052343 Gastrins Proteins 0.000 title abstract 6
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title abstract 2
- YDZYKNJZCVIKPP-VWLOTQADSA-N netazepide Chemical compound CNC1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 YDZYKNJZCVIKPP-VWLOTQADSA-N 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000001132 Osteoporosis Diseases 0.000 title 1
- 229950010986 netazepide Drugs 0.000 title 1
- 208000020084 Bone disease Diseases 0.000 abstract 3
- 206010060377 Hypergastrinaemia Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Las modalidades proporcionadas se basan en algunos aspectos en la demostración en la presente de un papel para la gastrina en la regulación del envejecimiento del eje de los intestinos-ovarios, y en los efectos de dirigir la actividad de la gastrina en la reversión de la pérdida ósea mediada por la gastrina; se proporcionan métodos, composiciones y agentes, incluyendo antagonistas de gastrina, por ejemplo antagonista del receptor CCK2 (en particular YF476), para el tratamiento, la mejora y la prevención de enfermedades y condiciones óseas; los métodos para el tratamiento de una enfermedad o condición ósea asociada con hipergastrinemia en un sujeto en necesidad del mismo, pueden comprender la administración al sujeto de al menos una dosis de una cantidad terapéuticamente eficaz de un agente dirigido al receptor de gastrina, tratando así la enfermedad o condición ósea asociada con la hipergastrinemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907980P | 2013-11-22 | 2013-11-22 | |
| PCT/US2014/066832 WO2015077572A1 (en) | 2013-11-22 | 2014-11-21 | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006657A true MX2016006657A (es) | 2016-10-12 |
Family
ID=52118000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006657A MX2016006657A (es) | 2013-11-22 | 2014-11-21 | Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10709714B2 (es) |
| EP (1) | EP3071206B1 (es) |
| JP (1) | JP6502939B2 (es) |
| KR (1) | KR102254957B1 (es) |
| CN (1) | CN106163527A (es) |
| AU (1) | AU2014352875B2 (es) |
| BR (1) | BR112016011727A2 (es) |
| CA (1) | CA2929858C (es) |
| DK (1) | DK3071206T3 (es) |
| ES (1) | ES2870538T3 (es) |
| MX (1) | MX2016006657A (es) |
| PL (1) | PL3071206T3 (es) |
| RU (1) | RU2693484C1 (es) |
| WO (1) | WO2015077572A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10881667B2 (en) | 2018-10-30 | 2021-01-05 | City University Of Hong Kong | Method and composition for treating epilepsy |
| US11285161B2 (en) | 2019-04-26 | 2022-03-29 | City University Of Hong Kong | Method and composition for treating mental disorder and pain associated with nerve damage |
| CN110935005A (zh) * | 2019-11-19 | 2020-03-31 | 宁波大学 | 一种丙谷二肽的新用途 |
| CN115770266B (zh) * | 2023-01-30 | 2023-05-09 | 云南中医药大学 | 一种用于治疗绝经后骨质疏松的药物组合物 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4992437A (en) | 1987-12-22 | 1991-02-12 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compounds and their pharmaceutical use |
| DE69017302T3 (de) | 1989-08-04 | 1999-08-05 | Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire | Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. |
| US5399565A (en) | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
| CA2099672A1 (en) | 1990-12-25 | 1992-06-26 | Masato Satoh | Benzodiazepine derivatives |
| CA2110986A1 (en) | 1991-07-12 | 1993-01-21 | Geoffrey Neil Woodruff | Cholecystokinin antagonists useful in the treatment of panic attacks |
| JP3239364B2 (ja) | 1991-10-11 | 2001-12-17 | ウェルファイド株式会社 | 骨粗鬆症治療薬およびジアゼピン化合物 |
| WO1993012817A1 (en) * | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| IL104853A (en) | 1992-02-27 | 1997-11-20 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them |
| TW281669B (es) | 1993-02-17 | 1996-07-21 | Chugai Pharmaceutical Co Ltd | |
| GB2282595A (en) | 1993-08-25 | 1995-04-12 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives |
| IT1261255B (it) | 1993-09-09 | 1996-05-09 | Rotta Research Lab | Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico. |
| CA2239293A1 (en) | 1995-12-11 | 1997-06-19 | New England Medical Center Hosptials, Inc. | Assay for and uses of peptide hormone receptor ligands |
| US5750353A (en) | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
| US5922883A (en) | 1996-04-03 | 1999-07-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| NZ500748A (en) | 1997-05-12 | 2001-06-29 | Aphton Corp | Methods for the treatment of gastrin-dependent tumours comprising active or passive immunisation with an anti-CCK-B/gastrin receptor immunogen or anti-CCK-B/gastrin receptor antibodies |
| US20040001842A1 (en) | 1997-05-12 | 2004-01-01 | Dov Michaeli | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
| ES2237103T3 (es) | 1998-05-15 | 2005-07-16 | Aphton Corporation | Terapia de combinacion para el tratamiento de tumores. |
| SK18542000A3 (sk) | 1998-06-04 | 2001-12-03 | Abbott Laboratories | Protizápalové zlúčeniny inhibujúce bunkovú adhéziu |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| EP1156037B1 (en) | 1999-01-29 | 2004-12-01 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US20030191279A1 (en) | 1999-08-27 | 2003-10-09 | Goldstein Steven Wayne | Urea derivatives useful as anticancer agents |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| IL149177A0 (en) | 1999-11-05 | 2002-11-10 | Sod Conseils Rech Applic | Novel heterocyclic compounds and their use as medicines |
| JP2003513995A (ja) | 1999-11-19 | 2003-04-15 | アクスクシーマ ファルマシューティカルス アクチェンゲゼルシャフト | ヘリコバクターピロリにより誘発される胃腸疾患の阻害剤 |
| AU2001253024A1 (en) | 2000-04-10 | 2001-10-23 | The General Hospital Corporation | Diagnosis and treatment of gastrointestinal disease |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| JP2005508838A (ja) | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
| JPWO2002087620A1 (ja) | 2001-04-27 | 2004-08-12 | 中外製薬株式会社 | 軟骨形成促進剤 |
| US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| US20040138207A1 (en) | 2001-05-11 | 2004-07-15 | Mayumi Yamano | Antitumor agents |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| CN100348196C (zh) | 2001-11-13 | 2007-11-14 | 詹姆士布莱克基金会有限公司 | 作为胃泌激素和缩胆囊肽受体配体的苯并三氮杂䓬 |
| US20040127492A1 (en) | 2002-02-19 | 2004-07-01 | Pharmacia Corporation | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| DE10207037A1 (de) | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| UA79804C2 (en) | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
| US20030049698A1 (en) | 2002-10-08 | 2003-03-13 | Wang Timothy C. | Diagnosis and treatment of gastrointestinal disease |
| WO2005012275A2 (en) | 2003-03-28 | 2005-02-10 | Janssen Pharmaceutica, N.V. | Benzo [1, 2, 5] thiadiazole compounds as cck2 modulators |
| US7524837B2 (en) | 2003-05-12 | 2009-04-28 | Janssen Pharmaceutica N.V. | Benzotriazapinone salts and methods for using same |
| GB0310865D0 (en) | 2003-05-12 | 2003-06-18 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| US20050042283A1 (en) | 2003-07-11 | 2005-02-24 | University Of Massachusetts | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| SI1651621T1 (sl) | 2003-08-08 | 2008-12-31 | Janssen Pharmaceutica Nv | 2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2 |
| WO2005090319A1 (en) | 2004-03-19 | 2005-09-29 | Arrow Therapeutics Limited | Process for preparing benzodiazepines |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7947833B2 (en) | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| MX2007003623A (es) | 2004-09-24 | 2007-09-11 | Johnson & Johnson | Compuestos sulfonamida. |
| WO2006044352A2 (en) | 2004-10-12 | 2006-04-27 | Janssen Pharmaceutica N.V. | Canine cholecystokinin 1 receptor materials and their use |
| JP2008518014A (ja) | 2004-10-27 | 2008-05-29 | ニューロゲン コーポレイション | Ｃｂ１拮抗薬としてのジアリール尿素 |
| AU2005305140A1 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as CB1 antagonists |
| GB0425196D0 (en) | 2004-11-15 | 2004-12-15 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| ATE405262T1 (de) | 2004-12-17 | 2008-09-15 | Pfizer | Chroman-derivate als säurepumpenantagonisten |
| PL1839662T3 (pl) | 2005-01-19 | 2010-08-31 | Zeria Pharm Co Ltd | Środek przeciwnowotworowy |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| JP5197361B2 (ja) | 2005-06-06 | 2013-05-15 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | 睡眠障害を処置するための組成物および方法 |
| CA2608582A1 (en) | 2005-06-14 | 2006-12-21 | Pfizer Inc. | Chromane substituted benzimidazole derivatives as acid pump antagonists |
| EP1747800B1 (en) | 2005-07-29 | 2009-03-18 | Rottapharm S.p.A. | Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders |
| WO2007026218A2 (en) | 2005-09-01 | 2007-03-08 | Pfizer Japan Inc. | Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists |
| WO2007031860A1 (en) | 2005-09-15 | 2007-03-22 | Pfizer Japan Inc. | Indane substituted benzimidazoles and their use as acid pump inhibitors |
| CN101341149B (zh) | 2005-12-19 | 2011-06-08 | 拉夸里亚创药株式会社 | 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 |
| WO2007072142A2 (en) | 2005-12-19 | 2007-06-28 | Pfizer Japan Inc. | Benzimidazole-5-carboxamide derivatives |
| BRPI0708808A2 (pt) | 2006-03-17 | 2011-06-14 | Raqualia Pharma Inc | Derivados de cromano |
| AU2007236321A1 (en) | 2006-04-12 | 2007-10-18 | Merck Patent Gmbh | N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases |
| FR2901472B1 (fr) | 2006-05-24 | 2010-08-13 | Oreal | Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants |
| FR2901473B1 (fr) | 2006-05-24 | 2010-08-13 | Oreal | Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide |
| RU2412188C2 (ru) | 2006-09-21 | 2011-02-20 | Раквалиа Фарма Инк. | Производные бензимидазола в качестве селективных ингибиторов кислотной помпы |
| WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
| WO2008059373A1 (es) | 2006-11-17 | 2008-05-22 | Raqualia Pharma Inc. | Vacuna contra la malaria, basada en la subunidad 200l de la proteína msp1 de plasmodium vivax. |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| WO2008114123A1 (en) | 2007-03-21 | 2008-09-25 | Raqualia Pharma Inc. | Spiro benzimidazole derivatives as acid pump inhibitors |
| WO2008124518A1 (en) | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| WO2008124524A2 (en) | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Aryl sulfonamide compounds as modulators of the cck2 receptor |
| EP2173721B1 (en) | 2007-06-26 | 2011-12-28 | Sanofi | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| RU2379043C2 (ru) | 2007-08-02 | 2010-01-20 | Закрытое акционерное общество "Биологические исследования и системы" | Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы |
| WO2009020768A1 (en) | 2007-08-07 | 2009-02-12 | President And Fellows Of Harvard College | Targeting the oncoprotein nucleophosmin |
| TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| AU2010231439A1 (en) | 2009-03-31 | 2011-10-27 | Zeria Pharmaceutical Co., Ltd. | Method for manufacturing 1,5-benzodiazepine derivative |
| JP5802898B2 (ja) | 2009-07-09 | 2015-11-04 | ラクオリア創薬株式会社 | 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤 |
| EP2480549B1 (en) | 2009-09-24 | 2015-04-08 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Fused imidazo[3,2-d]pyrazines as PI3 kinase inhibitors |
| SI2485731T1 (sl) | 2009-10-06 | 2016-09-30 | Millennium Pharmaceuticals, Inc. | Heterociklične spojine, ki se uporabljajo kot inhibitorji pdk1 |
| US9181414B2 (en) | 2009-11-13 | 2015-11-10 | Plastipak Packaging, Inc. | Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions |
| WO2011063164A2 (en) | 2009-11-18 | 2011-05-26 | Steady Sleep Rx Co., Inc. | Sustained release cannabinoid medicaments |
| AU2011242683A1 (en) | 2010-04-23 | 2012-12-13 | Kineta, Inc. | Anti-viral compounds |
| BR112013003332B1 (pt) | 2010-08-12 | 2018-11-13 | Senomyx, Inc. | método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado |
| US20130281523A1 (en) | 2010-11-18 | 2013-10-24 | Peter LETENDRE | Low dose cannabinoid medicaments |
| US20120231083A1 (en) | 2010-11-18 | 2012-09-13 | The Board Of Trustees Of The University Of Illinois | Sustained release cannabinoid medicaments |
| JP2014503528A (ja) | 2010-12-14 | 2014-02-13 | エレクトロプホレトイクス リミテッド | カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用 |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| JP6210996B2 (ja) | 2011-11-07 | 2017-10-11 | マサチューセッツ インスティテュート オブ テクノロジー | Ｚ選択的オレフィンメタセシスのためのタングステンオキソアルキリデン錯体 |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
-
2014
- 2014-11-21 RU RU2016124538A patent/RU2693484C1/ru active
- 2014-11-21 CA CA2929858A patent/CA2929858C/en active Active
- 2014-11-21 KR KR1020167015759A patent/KR102254957B1/ko active IP Right Grant
- 2014-11-21 JP JP2016533607A patent/JP6502939B2/ja active Active
- 2014-11-21 WO PCT/US2014/066832 patent/WO2015077572A1/en active Application Filing
- 2014-11-21 US US14/550,233 patent/US10709714B2/en active Active
- 2014-11-21 ES ES14815149T patent/ES2870538T3/es active Active
- 2014-11-21 BR BR112016011727A patent/BR112016011727A2/pt not_active Application Discontinuation
- 2014-11-21 CN CN201480073822.0A patent/CN106163527A/zh active Pending
- 2014-11-21 MX MX2016006657A patent/MX2016006657A/es unknown
- 2014-11-21 AU AU2014352875A patent/AU2014352875B2/en active Active
- 2014-11-21 DK DK14815149.1T patent/DK3071206T3/da active
- 2014-11-21 EP EP14815149.1A patent/EP3071206B1/en active Active
- 2014-11-21 PL PL14815149T patent/PL3071206T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014352875A8 (en) | 2016-06-30 |
| JP2016538295A (ja) | 2016-12-08 |
| EP3071206B1 (en) | 2021-02-17 |
| RU2693484C1 (ru) | 2019-07-03 |
| US20150148339A1 (en) | 2015-05-28 |
| US10709714B2 (en) | 2020-07-14 |
| ES2870538T3 (es) | 2021-10-27 |
| DK3071206T3 (da) | 2021-05-25 |
| KR102254957B1 (ko) | 2021-05-25 |
| BR112016011727A2 (pt) | 2017-08-08 |
| EP3071206A1 (en) | 2016-09-28 |
| CA2929858A1 (en) | 2015-05-28 |
| PL3071206T3 (pl) | 2022-01-17 |
| AU2014352875B2 (en) | 2019-10-24 |
| JP6502939B2 (ja) | 2019-04-17 |
| WO2015077572A1 (en) | 2015-05-28 |
| CA2929858C (en) | 2022-03-29 |
| KR20160088891A (ko) | 2016-07-26 |
| AU2014352875A1 (en) | 2016-05-26 |
| CN106163527A (zh) | 2016-11-23 |
| RU2016124538A (ru) | 2017-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| UA122868C2 (uk) | Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MY182454A (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| IN2012DN00754A (es) | ||
| NZ739392A (en) | Methods for treating hepcidin-mediated disorders | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
| MY201535A (en) | Therapeutic compounds | |
| MX2016006657A (es) | Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis. | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| PH12017501736A1 (en) | Indole derivatives | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MY195960A (en) | Benzoic Acid Salt for use in Preventing or Treating Anti-N-Methyl-D-Aspartate Receptor Encephalitis |